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1. Introduction
The incidence of primary tumors of the central nervous system (CNS) has been estimated in
15.8/100,000 and 17.2/100,000 individuals for men and women, respectively [1,2], which
globally represents approximately 190,000 new cases per year. They represent the 3rd most
common cause of death from cancer in middle-aged men, and the 4th most common in
women between 15 and 34 years of age [3,4]. The most frequent tumors called gliomas ex‐
hibit glial characteristics on pathologic examination [1,3]. Despite advances in the knowl‐
edge of the molecular biology of gliomas, effective therapeutic strategies remain elusive.
After multimodality treatment with surgery, radiation and chemotherapy, the overall sur‐
vival (OS) of patients with Glioblastoma (GB), the most frequent glioma, is around 14.6
months and the survival at 2 years is 26% [5, 6, 7, 8]. Although it is recognized that there are
progenitor cells that can differentiate into neuronal and glial cells, the concept of a brain tu‐
mor stem cells is more controversial. In 2002, Altman and colleagues proposed the theory of
post-natal neurogenesis that, associated with the finding of progenitor cells in glial tumors,
suggested that these cells could be targeted for more effective therapies[9]. One of the diffi‐
culties is that there are no specific phenotypic markers for these cancer stem cells, and,
therefore, their identification is limited to a functional characterization.
Nonetheless, pluripotent cells obtained from human brain tumors that express the CD133
surface marker (or Prominin 1; PROM1 is the founding member of pentaspantransmem‐
brane glycoproteins) have the ability for sustained self-renewal, proliferation and tumor ini‐
tiation/propagation. Furthermore, this functionally defined glioma stem cells form a niche
around the blood vessels, being highly pro- angiogenic; those are regulated by hypoxia and
are resistant to conventional oncologic treatment like radiotherapy and/or chemotherapy
[10, 11]. In addition, they have important migration and invasion capabilities while actively
interacting with the immune system. Therefore, therapeutic opportunities include targeting
of stem cell specific pathways, induction of differentiation of stem cells, blocking microen‐
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vironment signals (including angiogenesis factors), and harnessing the immune system to
recognize and attack stem cells. Significant challenges continues since the presence of cancer
stem cells within the tumor is highly heterogenous, they can remain quiescent for years, and
they may share biological features with normal stem cells [12, 13].
We present here a detailed review of the published literature on cancer stem cells of gliomas
and meduloblastomas, and their possible relationships with the response to chemo-radio‐
therapy and to future therapeutic interventions. Similarly, we discuss their role in the pro‐
gression of the disease, and we provide an analysis of the functional properties of neuronal
progenitor cells and of their tumor homologues that lose their regulatory capacity during
the process of neurogenesis.
2. Identification of progenitor cells in the brain and the relationship with
glial tumors
Cancer only develops after mutations occurs in a few cells. These abnormal cells lose the ca‐
pacity for self -regulation and have the potential for uncontrolled proliferation [12]. Two hy‐
pothetical models have been invoked to explain this phenomenon. The first is the
“stochastic” which predicts that all cells have a homogeneous capacity to initiate a neoplasm
with areas in which the elements are activated in a synchronic and constitutive manner [12].
The second model is the “hierarchic” which assumes that only a sub-group of cells in the
tumor has the potential to proliferate and to generate new neoplasic focus; the other cells act
as support or representate well-differentiated or terminal tumor cells. This model explains
the findings of the pluripotent progenitor cells in acute myeloid leukemia, in cerebral tu‐
mors, and in cancer of the breast, prostate and colon [13, 14]. Nevertheless, those two mod‐
els are not exclusive and it is likely that there is a combination of both scenarios in most
types of cancer. Fig. (1) Summarizes the principal molecular alterations of cerebral tumors of
glial origin.
Early studies by Nottebohm et al. reported the discovery of neural embryonic tissue in the
cerebral parenchyma of birds [15],followed by reports of similar findings in rodents, pri‐
mates and humans [16]. As a consequence, it is generally accepted that neurogenesis persists
during adulthood, particularly at the level of the dentate gyrus of the hippocampus (in the
hilus and in several planes of the granular laminae) and in the upper region of the deep lat‐
eral ventricles, neighboring the striated body, as shown in Fig. (2).These cells constitute
about 0.2% of the elements forming the encephalon, primitively associated with the telence‐
phalon and generally expressing the glial fibrillary acidic protein (GFAP) [16, 17]. They have
a putative role in, and are capable of regenerating the neurogenetic structure in vivo and in
vitro; generally enjoying a state of relative quiescence with a cell cycle of about 28 days (type
B cells or pluripotent astrocytes) [18].
Usually, the pluripotent progenitor cells have a capacity of generating other second-order
progenitor elements that divide every 12 hours (rapid proliferation phase). These cells,
termed type C (immature precursors), maintain multipotent capacity and generate other
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neuronal precursors with greater maturity, termed type A cells (migrant neuroblasts). This
type A cells are capable of migrating in groups across the rostral portion of the lateral ven‐
tricle up to the olfactory bulb where they are integrated as new interneurons in different lay‐
ers of the cortex (Fig. 2) [19].The subventricular stem cells are conserved in eutherian
mammals, but only in man is the cellular displacement not grouped, but rather individual;
and follow a destiny that, as-yet, has not been clarified [20]. Analogously to the subventricu‐
lar zone, the hippocampus granular region amplifies some lesser-known precursor cells
termed type D, which have limited migratory capacity (short distances) [20].
From the neurochemical perspective, the type B cells express intermediate filaments such as
vimentin and nestin, and are characteristically negative for the neuronal markers PSA-
NCAM (Poly-Sialated Neural Cell Adhesion Molecule) and TuJ1 (class III beta-tubulin) [21].
They frequently express PDGFR-α (platelet-derived growth factor receptor) which appears
to act as a regulator of balance for the differentiation between the oligodendrocytes and neu‐
rons during the phase of asymmetric neurogenesis. The type B cells, while being highly sen‐
sitive to stimulation by epidermal growth factor (EGF) and FGF2 (fibroblast growth factor
type 2) [20], show constitutive positivity for CD133.
The expression of CD133 marker has been observed in normal progenitor cells, glial tumors
and central nervous system neoplasms (“neurosphere” model) [22, 23]. CD133 is a 130 KDa
surface glycoprotein with 5 transmembrane domains [24]. There are several isoforms of
CD133 regulated by methylation, but their specific regulatory roles in transcription are still
unknown [24]. Some reports suggest that their position in the membrane has some relation‐
ship with the dynamic organization of cell structure and, as such, determines cell polarity,
migration and interaction with other neighboring cells, especially with those belonging to
the tumor endothelium [21, 25]. The CD133 positive (CD133+) cells have a series of mecha‐
nisms that contribute to preferential activation of regulatory points of the cell cycle, increas‐
ing its resistance to standard chemotherapy and radiation therapy. [26]. This finding and
other routes of abnormal activation such as Wnt/β-catenin (Wnt was coined as a combina‐
tion of Wg and Int and can be pronounced as 'wint'), Notch (The notch signaling pathway is
a highly conserved cell signaling system present in most multicellular organism), SHh (son‐
ic-hedgehog), PTEN (phosphatase and tensin homolog) and Bmi-1 (polycomb ring finger
oncogene) explain, at least in part, why progenitor cells of glial tumors are resistant to radio‐
therapy [26, 27]. In addition, these cells exhibit primary resistance to chemotherapy agents
like carboplatin, paclitaxel and etoposide [28, 29].
GB are remarkably heterogeneous tumors, both phenotypically and genetically, and it is
very unlikely that a single antigen will selectively identify a single population of uniquely
tumorigenic cells that is common to all GBs. It is important to note that CD133-negative
brain tumor cells can also generate tumors in murine cancer models, and those new cells can
express CD133 in celular membrane [30]. In human tissue, another investigation have
shown that A2B5, a glial progenitor marker, is expressed in human gliomas, up to 61.7% of
tumoral cells, viewed on flow cytometry [31]. It would be considered that the role of CD133+
cells, versus the rest of the cell population, in brain tumor initiation and progression is still
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uncertain, but most of studies and models agree with the importance of CD133+ cells in tu‐
morgenesis on the brain [16-29].
A study that evaluated the genetic expression of the BCRP1/ABCG2 (also known as Abcg2
murine/ABCG2 human) and MGMT (O-6-methylguanine-DNA methyltransferase) in glial
progenitors found a significant increase in their activity, similar to various apoptosis sup‐
pressors such as Bcl-2 (B-cell lymphoma 2, apoptosis checkpoint), FLIP (inhibitory protein),
BCL-XL ("B-cell lymphoma-extra large", involved in the signal transduction pathway of the
FAS-L.) and of some inhibitors of pro-apoptosis proteins such as XIAP (Co-chaperone of The
hsp90, immunophilin homolog XAP2), cIAP1 (cellular inhibitor of apoptosis 1), cIAP2 (cellu‐
lar inhibitor of apoptosis 2), NAIP (neuronal apoptosis inhibitory protein) and survivin (ba‐
culoviral inhibitor of apoptosis repeat-containing 5 or BIRC5) [23]. Furthermore, the
inhibition of the caspases 3, 7 and 9 is significantly higher in recurrent GB rich in CD133+
cells than in its counterpart in which lower counts are observed [32].
Nestin, an intermediate class IV filament that is produced in considerable quantities in nor‐
mal and tumor progenitor cells during brain development and in glial neoplasms [33, 34], is
a constituent part of the cytoskeleton, has the responsibility for the maintenance of the cell
morphology and facilitates adhesion, proliferation and migration. In adults, nestin is ex‐
pressed in the subventricular progenitor cells, in some remnants near the choroid plexus
and in the prosencephalon [35]. As in high grade gliomas, nestin is re-expressed in multiple
cell lines of the brain during other circumstances such as acute ischemia, trauma and menin‐
go-encephalitis [36]. In neoplasms, the co-expression of nestin and vimentin is related to
substantial increase in invasive capacity (associated with multifocality), the facility to repair
external attack (nuclear nestin regulates chromatin), and motility. This combination of mark‐
ers could be useful in assessing the prognosis, especially since its presence is associated to a
more aggressive tumor phenotype, rich in progenitor cells [37].
The normal and tumor precursor cells share the expression of multiple markers, the capacity
of unlimited regeneration, exponential proliferation and open differentiation. Additionally,
they have similar telomerase activity and resistance to apoptosis, as well as a higher capaci‐
ty to transport substances to membrane level [38]. The latter characteristic facilitates the exo‐
cyte of anti-neoplastic molecules via proteins of the ABC family, such as MDR-1 (Gene that
encodes P-glycoprotein; ABCB1, ATP-binding cassette, sub-family B member 1), MRP-1 (hu‐
man multidrug resistance protein or ABCC1), ABCA2, ABCA3 and ABCG2 (Genes that enc‐
odes the ATP-binding cassette sub-family A member 2 protein, sub-family A member 3
protein and sub-family G member 2 protein; respectively) [21, 38, 39].
3. Molecular changes that favor tumor progenitor cells
The progenitor cells of brain tumors have certain characteristics that differentiate them from
their normal counterparts. By definition, the cancer stem cells need to have the capacity to
develop tumors following orthotopic implantation (if the tumor is an identical phenotypic
copy of the original tumor). They exhibit a sustained capacity for self-renewal and are capa‐
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ble of showing polyclonality [33]. Reilly et al. established a murine model that combined
mutations in the p53 gene and in the gene specific for neurofibromatosis (Nf1, neurofibro‐
min 11), capable of activating the Ras (a protein superfamily of small GTPases) pathway to
favor the formation of astrocytomas. They found that the deletion of any tumor suppressor
gene and/or the activation of oncogenes such as Ras and Akt (serine/threonine protein kin‐
ase) in the undifferentiated cells that express CD133 or nestin, resulted in the formation of
glial tumors [40].
Another important alteration is view on PDGF. The effect of PDGF on the nestin-positive
progenitor cells is equivalent to that which occurs when the loss of CDKN2A (cyclin-de‐
pendent kinase inhibitor 2A), which codes for the INK4a (tumour suppressor protein) and
ARF (ADP-ribosylation factor 11) is combined with the increase in the expression of EGFR
in the immature and in the mature cells [36,41]. Further, during embryogenesis neural pro‐
genitors have been shown to express the A isoform of the PDGFR, while its mature homo‐
logue (glia and neurons) is expressed on the PDGF surface. PDGFR-B is found in small
quantities in pluriultipotent cells, but only increases as the cells differentiate and mature, es‐
pecially into oligodendrocytes, and in the presence of phosphorylated PDGFR-A [42]. Infu‐
sion of PDGF-A in the subventricular region of certain rodents suppresses the production of
neuroblasts and generates a hyperplasia of type B cells which frequently results in the devel‐
opment of astrocytomas and oligodendrogliomas. Additionally, activation, via the PDGF
signaling, in the regions of the brain rich in precursor cells contributes to tumorigenesis,
which seems to be favored by autocrine and paracrine stimulation of PDGF-A, PDGF-B and
the OLIG2 (oligodendrocyte lineage transcription factor 2) transcription factors [42, 43].
Some of the signaling pathways included in the evolution of progenitor cells and in their
differentiation are altered in the gliomas. The Notch pathway is essential for the mainte‐
nance of tumor cell architecture. It is expressed from embryogenesis and interacts, normally
or abnormally, with multiple ligands such as DLL-1, 3 and 4 (delta-like 1, 3 and 4 respective‐
ly), together with the Jag-1 and Jag-2 proteins (jagged 1 and 2 respectively). The Notch sig‐
naling pathway controls neural differentiation and is known to maintain CNS character and
to inhibit neurogenesis. The Notch–Hes (Hairy and enhancer of split) pathway is necessary
for self-renewing cell division and, thus, maintenance of the neural precursor population
[44-47]. Another recent studies have shown that Fbw7 acts as a molecular switch that antag‐
onizes Notch activity and JNK/c-Jun signaling to enable neural stem cell differentiation and
progenitor survival [48]. In tumor progenitors, the Notch receptors has been shown acting
as a trigger for stimulation of differentiation [49] and, in preclinical studies, it has been
shown experimental therapeutic implications [50]. Differentiation is mediated by tumor ne‐
crosis factor- α (TNF-α) activator enzyme and by the C-secretase, which is responsible for
the signal transcription to the nucleus for unlinking responses via transcription factor CBF1/
Su(H)/LAG1 (CSL) (homologous Drosophila gene Suppressor of Hairless /Longevity assur‐
ance gene 1 or cardiolipinsynthetase) [49]. This interaction results in the activation of target
genes responsible for preempting differentiation and apopotosis [49] and gives the opportu‐
nity for developing therapeutic options [49, 50]. The Notch signaling pathway prevents the
degradation and ubiquitous distribution of nestin in the progenitor cells, and cooperates
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with K-Ras (v-Ki-ras2; Kirsten rat sarcoma viral oncogene homolog) in promoting colony
formation [49-51].
A study demonstrated that the inhibition of the Notch-1 receptor induces apoptosis and inhib‐
its the proliferation of glial cell tumors that express CD133 [52]. This provides an opportunity
to modulate the pathways responsible of treatment resistance, since there are compounds
available that act as decoys, as inhibitors of Υ-secretase, as intracellular bait directed against
MAML-1 (mastermind-like 1), or simply as inhibitors of the Ras pathway [53, 54].
Epithelial Growth Factor is another important issue in the molecular changes on progenitor
cells. Using the model of the neurosphere [22], Singh et al. inoculated cells isolated from
high grade glioma into the cranium of immuno-suppressed rodents and observed that the
minimum number of cells required to produce a neoplasm was 1x105. However, when the
experiment was repeated using CD133+ cells stimulated by EGF, the number required was
reduced to 100-fold [25, 55]. It is important to note that CD133 expression occurs not only in
the neural and neoplastic progenitor cells but also in endothelial stem cells that participate
in blood vessel formation necessary for the development of normal brain and for tumorigen‐
esis [55, 56]. In preclinical models, activated EGFR signaling induce behaviors characteristic
of GB on stem cells, including enhanced proliferation, survival and migration, even in the
absence of EGF ligand. wtEGFR block neuronal differentiation and is associated with a dra‐
matic increase in chemotaxis in the presence of EGF. EGFRvIII expression lead to an increase
in neural stem cells proliferation and survival, while it simultaneously blocked neuronal dif‐
ferentiation and promoted glial fate. It gives an opportunity for terapeutic development on
this EGF field [57].
4. The micro-environment of progenitor cells and glial tumors
The presence of progenitor cells in Acute Myeloid Leukemia highlights the importance of
the micro-environment in maintaining its function, and the quiescent state [9, 12, 14]. The
perivascular niche of the glial tumor progenitor cells is highly specialized and depends, in
great part, on the capillaries that are similar to those in the periventricular region of the hu‐
man brain. At the proximity to the endothelial cells, enables inter-cellular communication
that causes enrichment with brain derived neurotrophic factor (BDNF), vascular endothelial
growth factor C (VEGF-C) and pigment factor derived from the endothelium (PEDF) [9];
molecules that facilitate, principally, migration and neoplasic proliferation. Even more, there
is consistent evidence that the extra-cellular matrix is responsible for key points in the regu‐
lation of tumor precursors via the tenascin-C gene. Expression of this gene by the cells of the
neural crest translates into anti-adhesive properties that block the interaction of fibronectin
with the syndecans [58]. Further, chondroitin sulfate continues stimulating the progenitor
cell to maintain its primitive state, and impedes evolution of its progeny.
Although the niche affects the biology of the progenitor cells in the tumor, the communica‐
tion is not unidirectional. Several studies have demonstrated that the precursors are able to
promote the replication of endothelial cells, including the necessary stimulus for the forma‐
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tion of complex neovascular structures [59, 60] by increasing the concentrations of VEGF
and BDNF [9, 60, 61]. Complementing these data, Calabrese et al. found, using multi-photon
laser scanning microscopy, that the CD133+/nestin+ cells were always found in the intimal
layer proximal to the vascular endothelium of GB, medulloblastomas, ependymomas and
oligodendrogliomas [61].
Classically, pathology of high-grade gliomas describes a disorganized and aberrant vascular
growth randomly generated to supply the voracity of the tumor. However, several recently
published reviews explain that this architecture is available in the altered form to serve as
lodging for the tumor precursors and their vascular analogues [9, 14].
Glial progenitor cells and their descendants are capable of interfering with the blood vessels
of the brain, using the effect known as “perivascular satellitosis”. Nevertheless, it is infre‐
quent to find extra-axial lesions. Clinically, the microvascular density of GB correlates with
prognosis [62]; a factor that contributes to the response observed in anti-angiogenesis, possi‐
bly dependent on VEGF generated in elevated quantities by the CD133+ cells [63, 64]. Fur‐
ther, the observation that CD133+ GB cells lose their ability to recruit endothelial cells and
form blood vessels after being exposed to low concentrations of bevacizumab suggests that
this effect is controlled, at least in part, by the decrease in the expression of VEGF, VEGFR2
and angiopoietin-2 (Ang-2) [9].
Data from pre-clinical studies and clinical trials indicate that three drugs that block angio‐
genesis may be promising therapy for high-grade gliomas, due to their inhibitory potential
on the niche of tumor progenitors. An estudy demonstrated that endothelial cells increase
brain tumor stem cell survival and targeting the tumor vasculature with bevacizumab re‐
duces the number of cancer stem cells in treated tumors [65]. Bevacizumab (humanized
monoclonal antibody against VEGF receptors 1 and 2) and cediranib (AZD2171, potent in‐
hibitor of VEGF receptor tyrosine kinases type 1, 2 and 3) are being evaluated currently in
clinical trials. [65, 66, 67]Those are agents that act on the VEGF 1, 2 and 3 receptors, suggest‐
ing an improvement in progression- free survival (PFS) and OS in patients with recurrent
high grade gliomas. Cilengitide blocks the αvβ6, αvβ5 y αvβ3 integrins [68] and has been
evaluated in clinical trials [69, 70]. As previously mentioned, the effect of these molecules is
the normalization of the tumor vessels, or the depletion of the blood flow, that interferes
with the maintenance and survival of the precursor and terminal cells of the tumor, thus,
anti-angiogenic therapy may function as a therapy against Glioma Stem Cells. A further nu‐
ance has come from early studies that suggest that glioblastoma cells can form parts of the
tumor vasculature [71]. It is likely that anti-angiogenic drugs might not only inhibit tumor
vascularization to suppress GB growth, but also directly disrupt the niches for the mainte‐
nance of GSCs, therefore weakening the ‘‘tumor roots’’.
5. Role of progenitor cells in meduloblastomas
The two germinal epithelia of the cerebellum are found in the deep ventricular zone of the
velum of the posterior medulla and in the outermost layer of the metencephalon [72]. The
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matrix of the first of these regions gives rise to several neuronal and glial cell lines, and the
second, only produces granular cells which are the most numerous elements in all of the
prosencephalon [73]. In humans, peak growth of the cerebellum occurs later in comparison
with the remainder of the CNS, and its principal stage of development is in the third trimes‐
ter of gestation. In other more rudimentary mammalians this event occurs during the two
weeks following birth [74]. Nevertheless, evolution of this neural structure is observed in
children up to the end of the first year of life, and appears to be dependent on the presence
of the CD133+ cells, which are concentrated principally in the white matter and in the rhom‐
bic lips [75].
The evidence that connects the pluripotent neural cells with the tumor elements of the me‐
duloblastoma is merely correlative and is supported by the expression of the calbindin-D
(calcium binding protein D) among the precursors of normal cerebellum and, as well as be‐
ing found in 50% of the meduloblastomas, especially in those of the classical type. In con‐
trast, nodular lesions or desmoplasias express the marker p75, which suggests a dual tumor
origin. This hypothesis is supported by the behavior of the meduloblastomas induced in
murine models that frequently express CD133+ but which have a specific dissimilar evolu‐
tion such as, among other aspects, the aberrant activation of the Hedgehog (Hh) gene [76].
The Hh pathway regulates the development of the cerebellum in many species, but has car‐
dinal importance among humans, where it promotes migration of precursors of granular
cells, and their proliferation incited by the production of the Hh ligand in Purkinje cells. The
mutation in the PTCH (patched homolog 1) receptor which results in constitutive activation
of the Hh pathway is found in a great number of patients with sporadic meduloblastoma, as
well as in those with Gorlin syndrome, an autosomal dominant entity characterized by coex‐
istence of basal cell carcinomas and primitive neuroectodermal tumors [73, 75]. Approxi‐
mately 14% of the mice heterozygous for the PTCH mutation develop medulobastomas, in
which primary alterations of the precursors of the granular cells are frequently found, as
well as changes in the SMO (smoothened) and SUFU (suppressor of fused homolog) genes,
which are generators of this type of neoplasia in vivo [77]. Other animal models have dem‐
onstrated that meduloblastomas initiated by genetic changes in the different pathways of
Hh also result in the activation of this signaling pathway; in particular, the inactivation of
the CXCR6 (chemokine receptor CXCR6) that results in the expression of Gli1, Gli2 (GLI
family zinc finger 1 and 2), Ptc2 (Hh receptor Patched type 2) and Sfrp1(secreted frizzled-
related protein 1) proteins evident in the meduloblastomas, and which are susceptible to in‐
hibition of Hh with molecules such as cyclopamine, or with specific inhibitors such as Hh-
antagonist [78].
Another signaling pathway altered in sporadic and inherited meduloblastomas is the Wing‐
less/Wnt (wingless-type MMTV integration site family member) that regulates the prolifera‐
tion of progenitor cells in the deep ventricular region and in the hippocampus [9]. The loss
of Wnt1, a key effector of β-catenin, causes several abnormalities in the midbrain and in the
cerebellum, and is found over-expressed in classical meduloblastomas [79, 80]. Although its
role in the regulation of the pluripotent progenitors of the cerebellum is not clear, it appears
to depend on similar mutations to those identified in the patients with Turcot syndrome; an
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autosomal recessive condition caused by the loss of function of the adenomatous polyposis
gene, and which is present in 5% of meduloblastomas [80]. The mutations have also been
observed in a small subgroup of patients with primitive neuroectoderm tumors and results
in the decrease in expression of Axin-2 (plays an important role in the regulation of the sta‐
bility of beta-catenin in the Wnt signaling pathway); the gene that acts as negative regulator
of Wnt and which has been detected in a small group of patients with meduloblastoma [81].
The nuclear translocation of the β-catenin resulting in the activation of the Wnt pathway is
observed in 25% of the patients with meduloblastoma and, usually, corresponds to an ele‐
vated presence of the CD133 cells. Paradoxically, and in contrary to what occurs in high-
grade gliomas, their presence is associated with a favorable clinical evolution, related to the
absence of alterations in Hh and aberrations in chromosome 17 [82].
The Notch signaling pathway is observed to be active in the progenitor cells of the deep ven‐
tricular region and in the rhombic region. It promotes proliferation and survival and inhibits
cellular differentiation. The four isoforms of the receptor do not result in the same changes
in the cerebellum. For example, Notch-2 stimulates the proliferation of progenitors of the
granular neuromas, while Notch-1 is associated with their differentiation; a consistent find‐
ing in the classical forms of meduloblastomas [82]. Some primitive neuroectoderm tumors
show increase in the Notch-2 loci and in co-expression of the Hes1 pathway, that correlate
clinically with adverse prognosis; while other studies have provided evidence for alterna‐
tive and abnormal regulation Notch Hh pathway [72]. Finally, hypoxia and the protein
products that this activity generates, promote the proliferation of progenitor cells of the cer‐
ebellum stimulated by the Notch pathway; a finding that has been confirmed in medulo‐
blastomas [83]. Fig. (3) summarizes the principal signaling pathways of the neural
precursors of the cerebellum and of meduloblastomas.
Several subordinate pathways can promote the generation of meduloblastomas from neural
progenitor cells. The REN (renin) gene located on chromosome 17 promotes the differentia‐
tion of granular precursors, suppressing the Hh signals, an alteration that frequently results
in meduloblastoma [73]. The N-myc oncogene (v-mycmyelocytomatosis viral related onco‐
gene, neuroblastoma derived), which plays an essential role in cerebellum growth, is a pri‐
mary constituent of white matter of the Hh pathway in meduloblastoma and is observed to
be amplified in large cell variants, which favor a negative clinical outcome. Other transcrip‐
tion factors associated with the more primitive processes of progenitor cells of the cerebel‐
lum and tumor development are RE-1 (RE1-Silencing Transcription factor), OTX2
(orthodenticle homolog 2) and BMI1 (BMI1 polycomb ring finger oncogene) [72, 73]. A re‐
cent report described the substantial role of molecular alterations of CD15+/CD133− in the
induction of primitive neuroectoderm brain tumors [84].
6. Therapeutic implications of tumor progenitors
The prognostic implications of the presence of stem cells in gliomas has been examined in a
few clinical trials. A study that included 44 patients with GB treated surgically followed by
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radiotherapy and temozolamide (TMZ), evaluated the prognostic value of CD133 expression
and of the capacity of the tumor to generate CD133+ cells in culture. The CD133 status, as
determined by immunohistochemistry, had no prognostic value, but the in vitro capacity to
generate precursors was associated to a significant reduction in OS (HR: 2.50; 95%CI:
1.04-6.06; P = 0.004) of 8 (95%CI: 4.0-11.5) and 15 months (95%CI: 11.0-19.0) for tumors with
higher and lower quantity of CD133+ cells, respectively (P = 0.0002). Similarly, the PFS was
also associated to the ability to generate precursors from the tumor (3.5 months for high ver‐
sus 9.0 months for low grade; P = 0.0001). The CD133+ count was also associated with a
higher mortality risk (HR: 1.65; 95%CI: 1.05-2.60; P = 0.0285) [85]. A similar study examining
high grade oligodendrogliomas found that tumors without CD133+ cells had an improved
prognosis, and this marker predicted clinical outcome better than histological assessment
[86]. Another immunohistochemical analysis for nestin and CD133 of both, low grade and
high grade gliomas, revealed that their expression correlates with survival, with tumors that
co-express nestin+/CD133+ carrying a shorter survival [87]. These findings have stimulated
the active search for new therapeutic strategies directed against the precursors of cerebral
tumors, and their microenvironment.
Therapeutic interventions directed against cerebral tumor progenitor cells can be divided in‐
to three groups: firstly, directed towards provoking differentiation of the precursors; sec‐
ondly, designed to eliminate the progenitor cells inhibiting their multi-potentiality and
quiescence; thirdly, directed towards attacking the tumor microenvironment [88, 89].
The therapies that provoke differentiation of the progenitors focus on the capacity to reverse
the malignant state and, essentially, to recover the auto-regenerative property [90]. To-date,
two groups of medications affect differentiation: derivatives of retinoic acid and compounds
directed against epigenetic changes (histone deacetylators).
Among the compounds directed towards eliminating progenitor cells, the therapies of note
are those that are directed against tumor markers of progenitor cells expressed in cellular
membrane (antibodies against CD133+) [9], the inhibitors of the Hh pathway (cyclopamine,
NBT-272) [91], PPAR-γ agonists [92], TMZ [93], inhibitors of mTOR (sirolimus, everolimus,
temsirolimus, deforolimus) [94], derivatives of bone morphogenetic protein (BMP) [95], tar‐
get molecules directed against check-points that avoid damage induced by radiotherapy in
the progenitors (Chk1 and Chk2, checkpoint homolog type 1 and 2) [15], imatinib [96, 97]
and inhibitors of the ABCB super-family [98]. Similarly, it is important to mention the drugs
that modify the micro-environment, among which are the angiogenesis blocking drugs such
as bevacizumab [65], cediranib [67] and cilengitide [68, 69] and, equally, the inhibitors of
PI3K (phosphoinositide-3-kinase) that could act turning the medulloblastoma progenitors
closest to the vascular niche more sensitive to irradiation, as in vitro studies show for human
endothelial cells precursors [99]. Fig. (4) highlights some strategies directed against the cell
precursors of brain tumors.
The effect of retinoic acid on the CD133+ cells appears to be related to the repression of the
Wnt/β-catenin pathway that slows the proliferation accompanying over-expression of Axin
[100]. The same strategy is used in a preclinical model to test the effectiveness of combining
13-cis-retenoic acid with vorinostat (SAHA) in medulloblastoma cells in culture. Retinoic
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acid acts on the transcriptional activation of BMP-2 (Bone morphogenetic protein 2), and SA‐
HA facilitates the apopotosis controlling chromatin; effects that lead to an increase in the
sensitivity to cisplatin and etoposide [101]. Heat shock protein 90 (HSP90) operates as a sup‐
plier of β-catenin during its conformational maturation phase. The inhibitor 17-allylami‐
no-17-demethoxygeldanamycin (17-AAG) modifies the HSP90 phenotype and affects the
aberrant expression of the β-catenin. This enables the inhibition (in vivo and in vitro) of the
growth of several cell lines of glioma and their progenitors CD133+, and translates into an
increase in the effect of radiation on the GB; a finding that is more evident during exposure
to TMZ [102].
With respect to the preponderant role of Hh in the development of normal and tumor pro‐
genitor cells, Bar et al explored the effectiveness of cyclopamine in a subpopulation of pri‐
mordial GB cells [103]. In the study, 26% of the samples showed Gli (transcription factors
mediating the Hh pathway isolated from Glioblastoma) over-expression, a target function of
this pathway that was inhibited satisfactorily in 60% of the cases. The outcome was a signifi‐
cant decrease in the CD133+ progenitor growth. In parallel, the administration of cyclopa‐
mine on neurospheres inhibited the generation of new colonies, suggesting a regression of
the clonogenic capacity of the glioma progenitors.
Beier et al. demonstrated that TMZ is incapable of inducing death of the CD133+ cells. Pro‐
liferation was effectively inhibited by reducing its metabolism in vitro by 72% following 7
days of incubation [93]. Depending on the subtype of cells, TMZ induces arrest in the G2-M
transition or delay in the cell cycle at G2. However, in all the cultures, the cells at sub-G0
peak of apopotosis, was <8%. Genetical analysis shows that the pattern of presentation of
the promoter of the MGMT gene was greater among the negative cells, which does not ex‐
plain the susceptibility of the progenitors to the alkylating agent [93].
Glial progenitors and their progeny conserve a mechanism of homogeneous differentiation
promoted by BMP (bone morphogenetic protein) and its ligands, reducing slightly the quan‐
tity of CD133+ cells and favoring the increase in the astroglia and of the cellular elements,
similar to neurons. An study observed in some in vivo models that the therapeutic stimulus
of the different isoforms of BMP delays tumor growth and the potential for vascular inva‐
sion of the GB [104].
Cancer stem cells from GB specimens seems to be immune suppressive as they inhibit mito‐
gen T cell proliferation from normal donors [105].Therefore targeting specifically cancer
stem cells may revert the immune suppressive microenvironment induced by these cells, al‐
lowing a synergistic effect when combined with immune therapy. On the other hand GB de‐
rived stem cells may be a source of unique antigens that can be used for dendritic cell
vaccination, as has been demonstrated in the animal model [106].
As previously mentioned, the use of bevacizumab attenuates the capacity of the tumor pro‐
genitors to promote angiogenesis, and it will be seen not only following the regulation of
acidosis and hypoxia but also by the activation of oncogenes such as PTEN and EGFR [64,
107]. Cediranib, a pan-inhibitor of VEGF receptor, normalizes the blood vessels of the tumor
in patients with recurrent GB; the perilesional edema is alleviated and the capacity for pre‐
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production of the CD133+ progenitors and the endothelium precursor cells is reduced [66].
Cilengitide reduces the expression of αvβ3 integrin in the tumor micro-environment. The
migratory and proliferative capacity of the precursors is reduced by up to 60%; an effect that
appears to be dependent on the dose and on the co-expression of other surface antigens of
the endothelial cells (CD144 and von Willebrand factor) [68-70].
Aldehyde dehydrogenase function is used by cancer stem cells to repopulate a tumor mass
after chemotherapy cytoreduction. As in hematopoyetic stem cells, it would be spected that
inhibition of Aldehyde dehydrogenase helps differentiate cells. With the inhibition of alde‐
hyde dehydrogenase, stem cell division to non-stem daughter cells tends to become blocked.
Exist potent aldehyde dehydrogenase inhibitors on the market: chloral hydrate, chloram‐
phenicol, and disulfiram, that could be useful [108].
7. Conclusion
Our understanding about cancer and the relationship with the theory of stem cells is grow‐
ing up as the tumoral incidence around the world does.
Advances in molecular cell biology will give to the oncology physicians and scientist the
tools for understanding the processes underlying tumorgenesis and intracelullar processes
for viability, serving as possible targets in oncotherapy, diagnosis and prognosis.
Molecular characteristics that give susceptibility for brain tumors to some therapies encour‐
age the clinicians to become experts for giving the best therapeutic choices according to mo‐
lecular guidance for radio/chemotherapy or other alternatives, like biological therapy,
immunotherapy and experimental treatment options.
Future about stem cells as a chapter of brain tumors is on the road for establish individual‐
ized treatment profiles, depending on clinical, pathological and molecular characteristics of
patients and tumors, a traslational analysis from the molecules to the patients.
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